In fact, the strategies involving the reduction of PMP22 levels are potentially destined to be of limited translational potential, essentially due to the variation in PMP22 expression among CMT patients, thus requiring a very precise approach that must be tailored to each patient. This evidence concerns the gene PMP22 and Charcot-Marie-Tooth disease.